Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
about
Resistant mechanisms to BRAF inhibitors in melanomaCancer pharmacogenomics, challenges in implementation, and patient-focused perspectivesThe Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin CancerMEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapyMelanoma: oncogenic drivers and the immune systemEpigenetic mechanisms involved in melanoma pathogenesis and chemoresistanceMore than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future HoldsTherapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathwayNanoparticle-mediated drug delivery for treating melanomaAcquired and intrinsic resistance in cancer immunotherapyAdvances in CRISPR-Cas9 genome engineering: lessons learned from RNA interferenceTargeting cancer with kinase inhibitorsImpact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing researchThe shortest path is not the one you know: application of biological network resources in precision oncology researchLandscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentTracking the evolution of cancer cell populations through the mathematical lens of phenotype-structured equations.CIViC databaseMolecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to TherapyFuture paradigms for precision oncologyNegative feedback regulation of the ERK1/2 MAPK pathwayDynamics-Driven Allostery in Protein KinasesAutophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumorsA protein deep sequencing evaluation of metastatic melanoma tissuesMitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant TransformationFunction-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF InhibitorCombinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells.The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells.Systemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma.Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.ETS-targeted therapy: can it substitute for MEK inhibitors?Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanomaStandardization of A375 human melanoma models on chicken embryo chorioallantoic membrane and Balb/c nude miceActivated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.The MAPK pathway as an apoptosis enhancer in melanoma.Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.
P2860
Q26739717-A85EE3FE-30FC-4CFA-8562-C9659E0EFF2FQ26741009-CF42BE7E-FC90-4557-B5A9-A63D5E34DA22Q26747247-D75DE4B2-0B28-4F57-B72E-DBEBF127D2B7Q26771192-06B95ABA-2699-4C9A-B0B0-FA2A49D4EDD5Q26775598-C9EF3E97-5C18-438D-8D8A-5625530996B1Q26778761-3CFFEB6B-51DE-4602-A4C7-6E901BEB72A5Q26781662-B5704715-B119-45CD-9507-30134E1A5DB4Q26782222-8E6A3D5E-582E-42CA-985B-8FAA13CCEFCFQ26797238-A7CD8EA2-A584-46E0-953E-262BF25683F5Q26798379-286DDDF5-E920-42E6-B48D-72EF00CA723FQ26827701-83B1AD30-2027-4430-9452-58CA2CB1D902Q26852489-B8AB1C41-F3A7-4FDF-A517-4FA0D5B0556DQ26865765-4F371375-228B-493A-8A5D-29D86A2E1399Q26866122-E1F1EEB6-E134-4B95-92EE-C14E3D157C2AQ26999241-113E7E41-C8D1-46E2-816D-C0019C2AC84DQ27313653-5E40D36F-D9B2-46D1-8507-EDA76E326B7CQ27335464-D643474A-6130-4473-8354-3A8738460F10Q27612411-D1E724FF-5DC0-4BD6-89D3-147BF3AC6748Q28070028-CD5403DA-8743-4A71-A9C6-987AA0110BB4Q28078745-82D2FA29-E7C4-4476-99CD-B0F73589F7C7Q28079202-A6421937-54AD-441E-84B8-AF3A2FE907DEQ28081279-2D8D0FB0-C445-4CCC-828C-3AA879980A93Q28468571-0BD0E9B9-689D-44F0-8ABC-8A513592DC30Q28546229-3AB48463-536D-47AB-8AD9-7C69DBCCA15EQ28548302-C9E9524E-73B3-4379-BC8A-23B0D645FB4CQ29542169-17E47E59-7C37-45FE-B7A8-47CC08A46372Q30277902-F4EA796C-ACF8-4650-86CF-77CB15AF0A7CQ30620714-A78AD461-BE2C-40E4-9A25-5739766115CCQ30837718-0C17BE60-CC54-464A-8357-10EAA194BC6BQ30940472-7D350300-417B-4B65-9EDF-CE2A66F8190CQ33605879-03A16BE1-4FF1-4CB0-BADF-35124FCE9A72Q33638827-C12DF525-B3C9-4B91-90BB-17575FFC0102Q33659361-64BCA4F7-7FFA-44A6-AE29-067D35DBBF85Q33762715-0143BB6C-2075-4F0F-8482-84B07A0EB8E3Q33857709-5E3CD03A-796F-4241-B191-254CFA351256Q33884726-695B3143-2C63-4C13-A4C0-2F5A0BECC901Q34104135-3DA747D8-5F7B-4906-A47C-3C8D81EAB407Q34489987-BE5C004E-11A3-4003-83AB-ED5A02010C2DQ34662946-7BA4DB2E-2ECE-41D0-8F3E-237557E4CEA5Q34667825-E4F8C758-32C5-4D3D-AB43-3F4E10732885
P2860
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
@ast
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
@en
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
@nl
type
label
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
@ast
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
@en
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
@nl
prefLabel
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
@ast
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
@en
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
@nl
P2093
P50
P3181
P356
P1433
P1476
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
@en
P2093
Alexander M M Eggermont
Andreas Schlicker
Anirudh Prahallad
Christian Blank
Christina Mateus
Cor Lieftink
Davide Zecchin
Guus J J E Heynen
Ingrid Hofland
Jelle Wesseling
P2888
P304
P3181
P356
10.1038/NATURE13121
P407
P50
P577
2014-04-03T00:00:00Z
P5875
P6179
1045315782